Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2003
03/26/2003CN1404774A Health-care beverage for diabetic and preparation method
03/26/2003CN1103780C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
03/26/2003CN1103643C Film coatings and film coating compositions based on dextrin
03/26/2003CN1103602C Process for preparing pharmaceutical formulation containing insulin analog
03/26/2003CN1103598C Chinese Medicine for treating diabetes and preparation method thereof
03/26/2003CN1103590C Use of thiazolidinediones to prevent or delay on set of NIDDM
03/25/2003US6538149 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
03/25/2003US6538144 P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparation and use
03/25/2003US6538034 Methods of treating or preventing weight gain, obesity, and related disorders
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6538003 Pyridopyranoazepine derivatives, their preparation and their therapeutic application
03/25/2003US6537995 Heterocyclic carboxamides
03/25/2003US6537981 26,27-Homologated-20-EPI-2-alklidene-19-nor-vitamin D compounds
03/25/2003US6537969 Nutritional supplement for cerebral metabolic insufficiencies
03/25/2003US6537965 Novel parathyroid hormone (PTH) peptide derivatives. In particular, the invention relates to PTH PTH-2 receptor agonist or antagonist properties to the derivatives.
03/25/2003US6537784 Self-regulated apoptosis of inflammatory cells by gene therapy
03/25/2003US6537765 GPR10 as a target for identifying weight modulating compounds
03/25/2003US6537578 Once-a-day controlled release sulfonylurea formulation
03/25/2003US6537519 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
03/25/2003CA2237221C Protein kinase c inhibitor
03/25/2003CA2224093C Human vascular endothelial growth factor 2
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/21/2003WO2002022555A1 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
03/20/2003WO2003023408A1 Compositions and methods for aa4rp assay
03/20/2003WO2003023407A1 Methods of screening molecules that are used to prevent cardiovascular diseases
03/20/2003WO2003023018A2 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003023001A2 Novel proteins and nucleic acids encoding same
03/20/2003WO2003022994A2 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
03/20/2003WO2003022871A2 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
03/20/2003WO2003022870A1 Calcium-influx inhibitory factor and method of isolation thereof
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022849A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003WO2003022830A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003WO2003022825A1 Benzothiazepine derivatives for the treatment of hyperlipidemia
03/20/2003WO2003022820A1 Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022804A2 Method for the preparation of crystalline tetrahydrobenzothiepines
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022797A1 Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
03/20/2003WO2003022787A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003WO2003022360A2 Thermotherapy via targeted delivery of nanoscale magnetic particles
03/20/2003WO2003022305A1 Method for treating coumarin-induced hemorrhage
03/20/2003WO2003022304A1 Oxynthomodulin for preventing or treating excess weight
03/20/2003WO2003022299A1 Genobix agonists and antagonists for use in the treatment of metabolic disorders
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022288A1 Nutritional compositions for controlling blood glucose level
03/20/2003WO2003022286A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
03/20/2003WO2003022271A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022253A1 Dosage forms having prolonged active ingredient release
03/20/2003WO2003022239A2 Stable water in oil aminophylline emulsions
03/20/2003WO2003022216A2 Biaryl substituted purine derivatives as potent antiproliferative agents
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002090545A9 Nucleic acid coding for the cgl1 polypeptide and diagnostic and therapeutic application of said nucleic acid and of the cgl1 polypeptide
03/20/2003WO2002087556A9 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
03/20/2003WO2002081686A3 Nucleic acids binding a neuropeptide
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002074045A3 Production of pancreatic islet cells and delivery of insulin
03/20/2003WO2002072602A3 Somatostatin antagonists
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003US20030056240 Transgenic animal model for use in the treatment of diabetes
03/20/2003US20030055265 Oxazole derivatives
03/20/2003US20030055261 Compounds with growth hormone releasing properties
03/20/2003US20030055227 Process for obtaining lignan
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055093 For therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction
03/20/2003US20030055091 Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
03/20/2003US20030055079 For therapy and prophylaxis of metabolic disorders related to insulin resistance or hyperglycemia typically associated with obesity or glucose intolerance
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055062 Heteroaryl urea neuropeptide Y Y5 receptor antagonists
03/20/2003US20030055058 Administering to a mammal an angiotensin converting enzyme inhibitor and a protein-tyrosine phosphatase inhibitor for improving the cardiovascular risk profile
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055046 Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055037 Benzimidazole and indole derivatives as CRF receptor modulators
03/20/2003US20030055033 Azetidine derivatives, their preparation and pharmaceutical compositions containing them
03/20/2003US20030055027 For therapy of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites
03/20/2003US20030055019 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
03/20/2003US20030055004 GPE analogs and peptidominetics
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054498 Recombinant vector for use in gene therapy for insulin-dependent diabetes mellitus and therapeutic composition thereof
03/20/2003US20030054490 Isolated human phosphatase proteins, nucleic acid molecules encoding phosphatase proteins and uses thereof
03/20/2003US20030054082 Oil or fat composition
03/20/2003US20030054058 Vitex agnus castus extract
03/20/2003US20030054038 Mixture of drug and enteric acid polymer; neutralization
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054015 Mixture of vegetable oil, aromatic solvent and caffeine; nerve stimulant perfume
03/20/2003US20030054014 Administering fungi spores; aging resistance
03/20/2003US20030053990 Virus vectors and methods of making and administering the same
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
1 ... 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 ... 1298